Biotechnology

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

Gary Clark dissects Avance Clinical's bold move into Asia's booming biotech hubs, revealing why the region is now essential for global drug development.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

South Korean brand Lactomedi’s nationwide CVS launch signals a major shift in feminine care, blending K-Beauty innovation with advanced microbiome science.

South Korea's Wellness Innercell targets Indonesia's booming wellness market. Its Surabaya-first strategy reveals a calculated blueprint for navigating Southeast Asia.

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

AbbVie's latest dividend increase isn't just good news for investors; it's a window into the pharma giant's strategy for navigating future challenges.

A scientific shift from replacement to regeneration is fueling a market set to surpass $100B. But can new players navigate the regulatory and commercial hurdles?

An independent study reveals a Quebec-based platform dramatically improves patient outcomes and slashes clinical workload. Is this the new OS for healthcare?

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Life science labs are eagerly exploring AI, but new data reveals a major roadblock: a fragmented digital landscape that keeps true innovation just out of reach.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

New real-time imaging gives surgeons a 3D molecular map of cancer in the OR, poised to end the emotional and physical toll of reoperations for many.

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

A quiet revolution is underway in animal feed, with enzymes driving a $4.6B market. This isn't just about cost; it's a tech-fueled shift to profitability.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.